Literature DB >> 8998104

Glucagon therapy in the treatment of symptomatic bradycardia.

J N Love1, J M Howell.   

Abstract

Symptomatic bradycardia is commonly seen in the emergency department. Effective drug therapy for this clinical scenario is limited. Although glucagon has been used in no clinical trial in this setting, its cardiac activity may prove useful, particularly in the setting of beta-adrenergic blockade. We report a case series comprising three patients taking maintenance beta-blocker therapy who presented to the ED with symptomatic bradycardia and hypotension and in whom glucagon therapy obviated the need for further treatment. Further study is warranted to evaluate and define the role of glucagon in the treatment of symptomatic bradycardia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8998104     DOI: 10.1016/s0196-0644(97)70327-5

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

1.  Transient sinus arrest during continuous infusion of landiolol in an elderly patient.

Authors:  Manabu Ichikawa; Tadahiko Ishiyama; Kazuhiro Shibuya; Takashi Matsukawa
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

2.  Treatment of Aluminium Phosphide Poisoning with a Combination of Intravenous Glucagon, Digoxin and Antioxidant Agents.

Authors:  Zohreh Oghabian; Omid Mehrpour
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19

3.  Glucagon Increases Beating Rate but Not Contractility in Rat Right Atrium. Comparison with Isoproterenol.

Authors:  Beatriz Merino; Ivan Quesada; Jesús Hernández-Cascales
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 4.  Treatment for calcium channel blocker poisoning: a systematic review.

Authors:  M St-Onge; P-A Dubé; S Gosselin; C Guimont; J Godwin; P M Archambault; J-M Chauny; A J Frenette; M Darveau; N Le Sage; J Poitras; J Provencher; D N Juurlink; R Blais
Journal:  Clin Toxicol (Phila)       Date:  2014-10-06       Impact factor: 4.467

5.  Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors.

Authors:  James C Yao; Jennifer A Chan; Alain C Mita; Madan G Kundu; Karina Hermosillo Reséndiz; Ke Hu; Shoba Ravichandran; Jonathan R Strosberg; Edward M Wolin
Journal:  Onco Targets Ther       Date:  2017-06-27       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.